This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
A Deep Dive into ARK ETFs
by Neena Mishra
We highlight the best performing ETFs managed by Cathie Wood
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
by Zacks Equity Research
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update
by Kinjel Shah
Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 20%+ to over $310 million on COVID-19 testing and its mutations
Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU
by Kevin Cook
Her focus on disruptive innovation broke the mold of Wall Street money management.
3 Biotech Technological Developments to Watch Out For in 2021
by Kinjel Shah
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases
by Zacks Equity Research
Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.
5 Medical Outperformers That Might Lose Steam in 2021
by Zacks Equity Research
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
CRISPR Gene Editing: Owning the Future of Medicine
by Kevin Cook
In the Century of Biology, it pays to own the future of curing disease at the root.
Editas (EDIT) Submits Application to Start Study on EDIT-301
by Zacks Equity Research
Editas (EDIT) files an IND application to the FDA for beginning a phase I/II study of EDIT-301 to treat SCD.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock?
by Zacks Equity Research
Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.
CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares rise.
Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod
by Zacks Equity Research
Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Vertex to End Phase II Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.